Hatake K - Search Results

1

[Treatment of breast cancer by using trastuzumab, a molecular targeted therapeutic agent].

Hatake K, Terui Y, Ito Y. Hatake K, et al. Nihon Naika Gakkai Zasshi. 2005 Sep 10;94(9):1839-48. doi: 10.2169/naika.94.1839. Nihon Naika Gakkai Zasshi. 2005. PMID: 16223144 Review. Japanese. No abstract available.

2

[Rituximab and hematological malignancy].

Hatake K, Mishima Y, Terui Y. Hatake K, et al. Nihon Rinsho. 2004 Jul;62(7):1321-4. Nihon Rinsho. 2004. PMID: 15283150 Review. Japanese.

3

5. Tanstuzumab treatment for breast cancer.

Hatake K, Tokudome N, Ito Y. Hatake K, et al. Intern Med. 2007;46(3):149-50. doi: 10.2169/internalmedicine.46.1783. Epub 2007 Feb 1. Intern Med. 2007. PMID: 17268136 Free article. Review. No abstract available.

4

[Resistance to rituximab and CD20 mutation].

Terui Y, Hatake K. Terui Y, et al. Among authors: hatake k. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:416-23. Nihon Rinsho. 2007. PMID: 17474440 Review. Japanese. No abstract available.

5

Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.

Furukawa K, Ito Y, Takahashi S, Sawaki M, Mizunuma N, Horikoshi N, Kasumi F, Akiyama F, Sakamoto G, Furukawa K, Tajiri T, Hatake K. Furukawa K, et al. Among authors: hatake k. Breast Cancer. 2006;13(4):329-33. doi: 10.2325/jbcs.13.329. Breast Cancer. 2006. PMID: 17146157 Free article.

6

Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.

Hatake K, Tokudome N, Ito Y. Hatake K, et al. Breast Cancer. 2007;14(2):132-49. doi: 10.2325/jbcs.977. Breast Cancer. 2007. PMID: 17485898 Free article. Review.

7

Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.

Osako T, Ito Y, Takahashi S, Tokudome N, Iwase T, Hatake K. Osako T, et al. Among authors: hatake k. Cancer Chemother Pharmacol. 2008 Jun;62(1):159-64. doi: 10.1007/s00280-007-0586-5. Epub 2007 Sep 20. Cancer Chemother Pharmacol. 2008. PMID: 17882419

8

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.

Tokudome N, Ito Y, Hatake K, Toi M, Sano M, Iwata H, Sato Y, Saeki T, Aogi K, Takashima S. Tokudome N, et al. Among authors: hatake k. Anticancer Drugs. 2008 Aug;19(7):753-9. doi: 10.1097/CAD.0b013e328302eb15. Anticancer Drugs. 2008. PMID: 18594220 Clinical Trial.

9

Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?

Ito Y, Iwase T, Hatake K. Ito Y, et al. Among authors: hatake k. Breast Cancer. 2012 Jul;19(3):206-11. doi: 10.1007/s12282-011-0266-5. Epub 2011 Apr 28. Breast Cancer. 2012. PMID: 21526426 Review.

10

[Rituximab resistance in B-cell lymphoma and its elimination].

Hatake K, Terui Y. Hatake K, et al. Gan To Kagaku Ryoho. 2009 Apr;36(4):548-51. Gan To Kagaku Ryoho. 2009. PMID: 19381025 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

471 results

Search Page